Sandro Santagata

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Intramedullary neuroma of the cervicomedullary junction. Case report
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02130, USA
    J Neurosurg Spine 5:362-6. 2006
  2. ncbi BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications
    Dora Dias-Santagata
    Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e17948. 2011
  3. ncbi CRX is a diagnostic marker of retinal and pineal lineage tumors
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e7932. 2009
  4. ncbi Using the heat-shock response to discover anticancer compounds that target protein homeostasis
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, United States
    ACS Chem Biol 7:340-9. 2012
  5. ncbi DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues
    Justin M Craig
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38881. 2012
  6. ncbi Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas
    Yongji Tian
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Mol Diagn 13:669-77. 2011
  7. ncbi Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content
    Coren A Milbury
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Mol Diagn 13:220-32. 2011
  8. ncbi Profiling critical cancer gene mutations in clinical tumor samples
    Laura E MacConaill
    Center for Cancer Genome Discovery, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 4:e7887. 2009
  9. ncbi Phase II study of protracted daily temozolomide for low-grade gliomas in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA 02115, USA
    Clin Cancer Res 15:330-7. 2009
  10. ncbi Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome
    Yoon Jae Cho
    Children s Hospital Boston, Boston, MA 02115, USA
    J Clin Oncol 29:1424-30. 2011

Collaborators

Detail Information

Publications13

  1. ncbi Intramedullary neuroma of the cervicomedullary junction. Case report
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02130, USA
    J Neurosurg Spine 5:362-6. 2006
    ..This case may represent the first true traumatic intramedullary neuroma of the CMJ diagnosed in a living patient and treated surgically...
  2. ncbi BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications
    Dora Dias-Santagata
    Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e17948. 2011
    ..1%) giant cell GBM (gcGBM). The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs...
  3. ncbi CRX is a diagnostic marker of retinal and pineal lineage tumors
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e7932. 2009
    ..To determine the biologic and diagnostic potential of CRX in human tumors of the retina and pineal, we examined its expression in multiple settings...
  4. ncbi Using the heat-shock response to discover anticancer compounds that target protein homeostasis
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, United States
    ACS Chem Biol 7:340-9. 2012
    ..From a chemical biology perspective, they define a robust approach for discovering candidate compounds that target the malignant phenotype by disrupting protein homeostasis...
  5. ncbi DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues
    Justin M Craig
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38881. 2012
    ..This study demonstrates that rigorous control of DNA fragment size improves aCGH performance. This methodological advance will permit the routine analysis of FFPE tumor samples for clinical trials and in daily clinical practice...
  6. ncbi Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas
    Yongji Tian
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Mol Diagn 13:669-77. 2011
    ..These results show that fusion transcripts and mutations can be detected reliably in standard FFPE specimens and may be useful for incorporation into future studies of pediatric gliomas in basic science or clinical trials...
  7. ncbi Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content
    Coren A Milbury
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Mol Diagn 13:220-32. 2011
    ..In summary, we demonstrate an efficient approach to increase screening capabilities from limited DNA material via multiplex-PCR and improve mutation detection sensitivity via COLD-PCR amplification...
  8. ncbi Profiling critical cancer gene mutations in clinical tumor samples
    Laura E MacConaill
    Center for Cancer Genome Discovery, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 4:e7887. 2009
    ..We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting...
  9. ncbi Phase II study of protracted daily temozolomide for low-grade gliomas in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA 02115, USA
    Clin Cancer Res 15:330-7. 2009
    ..Protracted treatment with temozolomide potentially overcomes MGMT resistance and improves outcome. We conducted a phase II study of protracted daily temozolomide in adults with low-grade gliomas...
  10. ncbi Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome
    Yoon Jae Cho
    Children s Hospital Boston, Boston, MA 02115, USA
    J Clin Oncol 29:1424-30. 2011
    ....
  11. ncbi High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:18378-83. 2011
    ..The findings indicate that HSF1 should be evaluated prospectively as an independent prognostic indicator in ER-positive breast cancer. HSF1 may ultimately be a useful therapeutic target in cancer...
  12. ncbi Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 31:836-45. 2007
    ....
  13. ncbi Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma
    Sandro Santagata
    Division of Neuropathology, Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Neurooncol 81:49-51. 2007